Pacific Biosciences of California, Inc. (PACB) has a consensus analyst rating of Buy, based on 18 analysts covering the stock. Of those, 9 recommend buying, 8 recommend holding, and 1 recommend selling.
The analyst consensus price target for PACB is $2.74, representing a +74.6% upside from the current price of $1.569. Price targets range from a low of $1.50 to a high of $4.00.
